Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer
Status:
Not yet recruiting
Trial end date:
2026-10-01
Target enrollment:
Participant gender:
Summary
This is a phase Ib followed by phase II clinical trial evaluating the safety and efficacy of
combination of ADG106 with pembrolizumab in patients with metastatic cancers. The Phase Ib
dose finding part will include all solid tumor subtypes with treatment refractory disease,
while phase II will focus on only patients with TNBC.